secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269492
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology Q3 cash $60.6M; Phase 2 trial shows 19% ORR improvement in mCRC
--------------------------------------------------------------------------------

- Onvansertib 30mg cohort showed 19% improvement in confirmed ORR vs control in RAS-mutated mCRC Phase 2 trial.
- Cash and investments $60.6M as of Sep 30, 2025; projected runway into Q1 2027.
- Net cash used in Q3 2025 was $10.8M, an increase of $0.3M from $10.5M in Q3 2024.
- Total operating expenses for Q3 2025 were $12.1M, down from $12.8M in the same prior-year period.
- Next clinical update from Phase 2 CRDF-004 trial expected in Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000119312525269492/0001193125-25-269492-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000119312525269492/crdf-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269492

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer